Coltuximab ravtansine (SAR-3419)
Revision as of 04:55, 23 November 2014 by Jwarner (talk | contribs) (Jwarner moved page SAR3419 to Coltuximab ravtansine (CoR, SAR3419))
Mechanism of action
Antibody-drug conjugate
Preliminary studies
- Abstract: B. Coiffier, V. Ribrag, J. Dupuis, H. Tilly, C. Haioun, F. Morschhauser, T. Lamy, C. Copie-Bergman, O. Brehar, R. Houot, J. M. Lambert, R. Morarui-Zamfir. Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). J Clin Oncol 29: 2011 (suppl; abstr 8017) link to original abstract